Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;24(2):171-7.
doi: 10.1016/j.janxdis.2009.11.004.

Minority participation in randomized controlled trials for obsessive-compulsive disorder

Monnica Williams  1 , Mark Powers, Yeo-Gin Yun, Edna Foa
Affiliations
Review

Minority participation in randomized controlled trials for obsessive-compulsive disorder

Monnica Williams et al. J Anxiety Disord. 2010 Mar.

Abstract

This paper reviews published randomized trials in North America to determine whether minority groups are underrepresented in clinical trials of OCD. A search of the literature produced 40 randomized trials of both adults and children with OCD, conducted in the U.S. and Canada from 1989 to 2009 (N = 3777). The groups included in this review were Caucasians/European Americans, Black/African-Americans, Hispanic/Latino-Americans, Asian-Americans, Others, and Unknown. Of these, 22 of 40 trials reported ethnic/racial information or data was available by request. We focused on the 21 trials from 1995 to 2008 providing ethnic/racial information, and among those (N = 2221), 91.5% of participants were Caucasian, 1.3% were African-American, 1.0% were Hispanic, 1.6% were Asian, 1.5% were Other, and 3.1% were Unknown. We conclude that minorities are underrepresented in North American OCD trials. Therefore, it is not known if empirically validated treatments are effective for these groups. Recommendations for improving recruitment of minorities for future studies are discussed.

PubMed Disclaimer

References

    1. Avery DR, Hernandez M, Hebl MR. Who’s watching the race? Racial salience in recruitment advertising. Journal of Applied Social Psychology. 2004;34:146–161.
    1. Beasley CM, Jr, Potvin JH, Masica DN, Wheadon DE, Dornseif BE, Genduso LA. Fluoxetine: no association with suicidality in obsessive–compulsive disorder. Journal of Affective Disorders. 1992;24:1–10. - PubMed
    1. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive–compulsive disorder. Archives of General Psychiatry. 1989;46:23–28. - PubMed
    1. Bergeron R, Ravindran AV, Chaput Y, Goldner E, Swinson R, Van Ameringen MA, et al. Sertraline and fluoxetine treatment of obsessive–compulsive disorder: results of a double-blind, six month treatment study. Journal of Clinical Psychopharmacology. 2002;22:148–154. - PubMed
    1. Chambless DL, Williams KE. A preliminary study of African-Americans with agoraphobia: symptom severity and outcome of treatment with in vivo exposure. Behavior Therapy. 1995;26(3):501–515.

Publication types

LinkOut - more resources